Aurinia Pharmaceuticals (IPHAF) has announced a positive cost-effectiveness assessment of LUPKYNIS (voclosporin) based on the Institute for Clinical and Economic Review (ICER) revised evidence report analysis.
Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).